Question 1

Am I eligible for this trial based on my current health and treatment history?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Study Assessing Adverse Events and Disease Activity of Intravenously (IV) Infused Telisotuzumab Adizutecan in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer clinical trial (NCT06614192). Contact the study team or your healthcare provider for specific answers.

Question 2

How does telisotuzumab adizutecan compare to my current treatment options?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Study Assessing Adverse Events and Disease Activity of Intravenously (IV) Infused Telisotuzumab Adizutecan in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer clinical trial (NCT06614192). Contact the study team or your healthcare provider for specific answers.

Question 3

What are the potential side effects of the treatments being tested?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Study Assessing Adverse Events and Disease Activity of Intravenously (IV) Infused Telisotuzumab Adizutecan in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer clinical trial (NCT06614192). Contact the study team or your healthcare provider for specific answers.

Question 4

How often will I need to come in for visits and tests during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Study Assessing Adverse Events and Disease Activity of Intravenously (IV) Infused Telisotuzumab Adizutecan in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer clinical trial (NCT06614192). Contact the study team or your healthcare provider for specific answers.

Question 5

What should I expect during the treatment process?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Study Assessing Adverse Events and Disease Activity of Intravenously (IV) Infused Telisotuzumab Adizutecan in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer clinical trial (NCT06614192). Contact the study team or your healthcare provider for specific answers.

Question 6

Are there any risks involved with participating in this trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the A Study Assessing Adverse Events and Disease Activity of Intravenously (IV) Infused Telisotuzumab Adizutecan in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer clinical trial (NCT06614192). Contact the study team or your healthcare provider for specific answers.

What this study is about